Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: Potential factors affecting the pharmacokinetic/pharmacodynamic target attainment
- 6 May 2019
- journal article
- research article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 125 (4) , 353-359
Abstract
Objectives: Cefoperazone/sulbactam trough concentration (Cmin) varies widely in cirrhotic patients. The objective of this study was to describe the characteristics of Cmin and to identify factors associated with the pharmacokinetic/pharmacodynamic (PK/PD) target attainment of cefoperazone/sulbactam in cirrhotic patients.Methods: Data were collected retrospectively from cirrhotic patients who received cefoperazone/sulbactam treatment. The Cmin was measured using a validated liquid chromatography‐tandem mass spectrometry. The PK/PD target of 100% fT > MIC was used for cefoperazone/sulbactam. Multivariate logistic regression and classification and regression tree (CART) analysis were performed to identify the factors affecting the PK/PD target attainment in these patients.Results: Cefoperazone and sulbactam Cmin were measured simultaneously in 103 plasma samples from 70 cirrhotic patients. Cefoperazone and sulbactam Cmin were 89.27 ± 44.38 mg/L and 10.09 ± 13.01 mg/L, respectively. The PK/PD target of 100% fT > MIC was achieved in 47.1% (33/70) patients for cefoperazone and in 28.6% (20/70) patients for sulbactam. The CART analysis revealed that cefoperazone Cmin was likely to reach the PK/PD target in patients with serum bilirubin levels between 26.15 μmol/L and 99.15 μmol/L. Inversely, lower cefoperazone Cmin was observed in patients with bilirubin levels ≤26.15 μmol/L and serum albumin >38.45 g/L or in patients with bilirubin levels >99.15 μmol/L and creatinine clearance (CrCl) >139.13 mL/min. Additionally, patients had higher sulbactam Cmin when CrCl was below 62.85 mL/min.Conclusions: This study shows that current cefoperazone/sulbactam dosage regimens may result in inadequate plasma concentrations in cirrhotic patients. We recommend monitoring the Cmin of cefoperazone/sulbactam to ensure efficacy of cefoperazone/sulbactam treatment.Keywords
Funding Information
- National Natural Science Foundation of China (81703618)
This publication has 22 references indexed in Scilit:
- Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis WorldwideGastroenterology, 2019
- EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosisJournal of Hepatology, 2018
- Basic & Clinical Pharmacology & Toxicology Policy for Experimental and Clinical studiesBasic & Clinical Pharmacology & Toxicology, 2018
- Bacterial distributions and prognosis of bloodstream infections in patients with liver cirrhosisScientific Reports, 2017
- Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapyInternational Journal of Antimicrobial Agents, 2017
- Nosocomial and Community-Acquired Spontaneous Bacterial Peritonitis in patients with liver cirrhosis in China: Comparative Microbiology and Therapeutic ImplicationsScientific Reports, 2017
- A study on the position and etiology of infection in cirrhotic patients: A potential precipitating factor contributing to hepatic encephalopathyExperimental and Therapeutic Medicine, 2013
- Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic ReviewAnnals of Intensive Care, 2012
- Management of bacterial infections in cirrhosisJournal of Hepatology, 2012
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973